Sparsentan’s launch time and approval information in China

Sparsentan (Sparsentan) has not yet received official marketing approval in China, so domestic patients are temporarily unable to purchase the drug directly through local medical channels. At present, the drug is still in the approval stage. For relevant clinical data and registration information, please pay attention to the latest announcement from the National Medical Products Administration (NMPA) in order to understand the official launch time and approval progress.

Since it is not yet on the market in China, patients who need to use sparsentan can only obtain it through overseas channels. The price of original research drugs in overseas markets is relatively high, about RMB 40,000 to RMB 50,000 per box. The high price is mainly due to research and development costs, international pricing strategies and import fees, which imposes a heavy financial burden on most patients.

Meanwhile, the Laotian version of generic spaxentan offers patients a more economical option. This version sells for about 7,000 to 8,000 yuan per box, which is significantly cheaper than the original drug. At the same time, the drug ingredients are basically the same as the original drug, and can meet certain clinical needs. However, when purchasing, you still need to pay attention to formal channels to ensure the quality and safety of drugs.

It is important to note that overseas drug prices are affected by exchange rate fluctuations, transportation costs and availability, so prices may change. When patients consider purchasing through overseas channels, they should consult a professional doctor in advance and choose a legal and safe purchase method to ensure drug safety and therapeutic effect.

Reference materials:https://www.drugs.com/